Prospective, randomized, multi-center, double-blind, controlled, two-period, two-treatment, crossover, adaptive enrichment phase II trial to evaluate the safety and efficacy of PD-Protec™ in peritoneal dialysis in patients with chronic renal failure

Trial Profile

Prospective, randomized, multi-center, double-blind, controlled, two-period, two-treatment, crossover, adaptive enrichment phase II trial to evaluate the safety and efficacy of PD-Protec™ in peritoneal dialysis in patients with chronic renal failure

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Alanylglutamine (Primary) ; Glucose
  • Indications Peritonitis; Renal failure
  • Focus Therapeutic Use
  • Sponsors Zytoprotec
  • Most Recent Events

    • 09 Jun 2017 Results from this trial published in a Zytoprotec Media Release.
    • 17 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2016 According to a Zytoprotec media release, the last patient has completed treatment in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top